ONT.LSE Oxford Nanopore Technologies Ltd

Healthcare Biotechnology London Exchange
2.09 GBX
Close of Nov 3, 2026
95.61 239.60
Market cap
GBX 2.05B
P/E
-
P/B
5.14x
ROE
-45.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ONT.LSE undervalued?

Graham number

The Graham number of Oxford Nanopore Technologies Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oxford Nanopore Technologies Ltd fundamental analysis

No fundamental analysis for Oxford Nanopore Technologies Ltd yet.

Oxford Nanopore Technologies Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oxford Nanopore Technologies Ltd

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, suc…

Full company profile